


c-Myc inhibitor 8

Cat. No.:	HY-148838
CAS No.:	2173505-97-8
Molecular Formula:	C ₁₉ H ₁₂ BrClF ₃ NO ₃ S ₂
Molecular Weight:	538.79
Target:	c-Myc
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	c-Myc inhibitor 8 (compound 56) is a c-Myc inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research ^[1] .
In Vitro	<p>c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of KU-19-19, 253J, J82, T24, MBT-2 and UM-UC-3 bladder cancer cell lines with IC₅₀s of 0.90, 1.11, 1.46, 0.98, 1.18 and 1.25 μM, respectively^[1].</p> <p>c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of A549, NCI-H460, MRC-5 and NCI-H23 hepatoma cell lines with IC₅₀s of 1.70, 1.90, 1.24 and 1.04 μM, respectively^[1].</p> <p>c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of MDA-MB-231, SK-BR-3, HCC1954 and MDA-MB-468 breast cancer cell lines with IC₅₀s of 1.45, 1.38, 1.47 and 1.64 μM, respectively^[1].</p> <p>c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of HL-60, U-937, Raji, Ramos (RAI), Daudi, Jurkat, MV-4-11 and MOLT-4 blood cancer cell lines with IC₅₀s of 1.95, 1.75, 1.12, 1.86, 1.25, 1.06, 1.50 and 1.66 μM, respectively^[1].</p> <p>c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of MIA PaCa-2 pancreatic cancer cell line with an IC₅₀ of 1.37 μM^[1].</p> <p>c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of HCT 116, SW620, HCT-15, RKO, HCT-8 and DLD-I colorectal cancer cell lines with IC₅₀s of 1.19, 1.91, 1.32, 1.53, 1.69 and 0.80 μM, respectively^[1].</p> <p>c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of U-251 MG, U-138 MG, LOX-IMVI, SK-HEP-I and OVCAR-3 cancer cell lines with IC₅₀s of 1.17, 1.34, 1.09, 1.02 and 1.09 μM, respectively^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>c-Myc inhibitor 8 (10 mg/kg; intraperitoneal injection, 3 times a week, for 10 days) inhibits tumor growth of human NCI-H1299 lung cancer mouse models^[1].</p> <p>c-Myc inhibitor 8 (30 mg/kg; intraperitoneal injection, 2 times a week, for 13 days) inhibits tumor growth of human prostate DU 145 cancer mouse models^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Jeong, Kyung Chae, et al. Anticancer pharmaceutical composition. WO2018021849. 2018.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA